Imvax
Philadelphia, Pennsylvania, United States · Biotechnology · 48 employees
Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspire™, focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. Imvax’s portfolio also includes several other programs design
Funding history
- Funding Round — $29.0M — Jan 2025
- Funding Round — $35.0M — May 2024
Recent signals
- Jan 29, 2025: Raised $29.0M
- Nov 11, 2024: Launched Imvax, Inc. to Present Safety Data on IGV-001 at the 2024 SNO Annual Meeting in Houston.
- May 21, 2024: Raised $35.0M
See plans & pricing → Track Imvax’s funding, hiring, and signals — with verified contacts — on Fundz.